Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Krazzy Rhino (specifically Krazzy Rhino 25000) is an unapproved male enhancement product marketed as a dietary supplement but flagged by the FDA for containing hidden sildenafil, the active pharmaceutical ingredient in Viagra. It is typically sold in single-serving packages at gas stations, convenience stores, and through online retailers. The product is not manufactured by a legitimate pharmaceutical company and is associated with illegal distribution networks. Because it contains undeclared phosphodiesterase type 5 (PDE5) inhibitors, it poses severe health risks, particularly for individuals using nitrates for heart conditions, as the combination can lead to life-threatening hypotension. Reported adverse effects include chest pain, severe headaches, and prolonged erections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Krazzy Rhino.